🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
DOT-C is a cluster randomised trial of a pharmacist-led, directly observed ...
Status
Completed
Location
Ninewells Hospital
Start Date
2015-11
Trial ID
NCT03483818
Treatments Being Tested
This study will evaluate the antiviral efficacy, safety, and tolerability o...
Status
Completed
Location
Multiple Locations
Start Date
2015-04
Trial ID
NCT02413593
To evaluate the drug-drug interactions between BI 201335 and BI 207127 as w...
Status
Completed
Location
1241.27.0006 Boehringer Ingelheim Investigational Site
Start Date
2012-04
Trial ID
NCT01525628
The purposes of the PLUS study were to confirm the safety and tolerability ...
Status
Completed
Location
Henry Ford Hospital
Start Date
2008-01
Trial ID
NCT00593151
Treatments Being Tested
The primary objectives of this study are to evaluate the antiviral efficacy...
Status
Completed
Location
Multiple Locations
Start Date
2015-06-17
Trial ID
NCT02472886
The purpose of this study is to assess the ability of eltrombopag to mainta...
Status
Completed
Location
GSK Investigational Site
Start Date
2007-10
Trial ID
NCT00529568
Treatments Being Tested
The project will evaluate cost and treatment outcomes of a simplified hepat...
Status
Completed
Location
Waimaw
Start Date
2017-12-20
Trial ID
NCT03579576
This is a two-arm cluster randomized control trial to evaluate the effectiv...
Status
Not Yet Recruiting
Location
Multiple Locations
Start Date
2026-08-01
Trial ID
NCT07560046
Parts A and B of this study are designed to evaluate the safety, tolerabili...
Status
Completed
Location
Multiple Locations
Start Date
2013-03
Trial ID
NCT01852604
The primary purpose of this study is to evaluate the safety, tolerability, ...
Status
Completed
Location
Multiple Locations
Start Date
2010-08
Trial ID
NCT01193478